🧾 What This Document Is

This is a Form 6-K, a report GSK files with the U.S. SEC as a foreign company. It's a formal announcement confirming the completion of a major ownership change within its key HIV business. Essentially, it’s the official "it's done" notice to investors.

🏢 ViiV Healthcare: The Crown Jewel

👉 In simple terms, ViiV Healthcare is GSK's specialist HIV and AIDS medicine business. It's not a new startup; it's a major, established global company focused solely on HIV treatment and prevention. GSK already owned a controlling majority stake in it, making ViiV a core part of GSK's pharmaceutical empire.

🤝 The Deal: Pfizer Out, Shionogi In

The key action here is a ownership reshuffle. Pfizer, which was a minority shareholder, has fully exited its investment in ViiV. Its entire 11.7% stake has been bought by Shionogi, another global pharmaceutical company based in Japan. This was not a simple stock sale; it involved ViiV itself issuing new shares to Shionogi.

💰 Financial Considerations & Windfall This transaction had a total price tag of $2.125 billion. Here’s where that money went:

• $1.875 billion went to Pfizer for its stake.
• $0.250 billion ($250 million) was paid to GSK as a special dividend. 👉 This is a direct cash payment to GSK, boosting its finances.

📊 New Ownership Structure & Strategic Impact

The deal cleanly reshapes ViiV's ownership:

• GSK: 78.3% (Maintains a strong, majority controlling share)
• Shionogi: 21.7% (Significantly increases its investment and commitment)

👉 Why this matters for GSK: GSK keeps full control of a highly valuable asset. By having Shionogi buy Pfizer out, GSK gains a larger, more committed long-term partner in the HIV business without having to spend its own cash to buy the stake. The $250 million special dividend is a nice immediate financial perk.

⚖️ Financial Accounting Cleanup

The filing notes a technical but important accounting move: a "put option liability" related to Pfizer's stake was removed from GSK's books. This liability represented a potential future obligation to Pfizer. Its removal cleans up GSK's balance sheet and eliminates associated financial uncertainty.

🔮 What's Next & The Bigger Picture

This is a final step in a process announced back in January 2026. It solidifies the strategic partnership between GSK and Shionogi around HIV. With Pfizer fully out of the picture, ViiV's ownership is now simpler and more aligned between two dedicated pharma companies. This likely streamlines future decision-making for the HIV business.

👍 Strengths & Signals

• Stronger Partnership: Deepens commitment from Shionogi, a proven partner with HIV expertise.
• Financial Gain: GSK receives a $250 million cash dividend.
• Cleaner Structure: Simplifies ownership, potentially making ViiV more agile.

⚠️ Potential Risks to Monitor

• The success of ViiV remains crucial to GSK's overall performance.
• The HIV market is competitive; ViiV must continue innovating to maintain its leading position.

🧠 The Analogy

Imagine a highly successful family restaurant. GSK is the majority owner (the head chef), Pfizer was an early silent investor, and Shionogi was a smaller investor who also supplied key ingredients. Pfizer decided to sell its share, so Shionogi bought it out, becoming a much larger partner. The head chef (GSK) keeps control of the kitchen, gets a cash payout from the deal, and now works with an even more invested and capable partner.

📇 Key Contacts & People

GSK Investor Relations:

• Constantin Fest: +44 (0) 7831 826525 (London)
• James Dodwell: +44 (0) 20 8047 2406 (London)
• Mick Readey: +44 (0) 7990 339653 (London)
• Steph Mountifield: +44 (0) 7796 707505 (London)
• Sam Piper: +44 (0) 7824 525779 (London)
• Jeff McLaughlin: +1 215 751 7002 (Philadelphia)
• Frannie DeFranco: +1 215 751 3126 (Philadelphia)

Shionogi Enquiries:

• Website Inquiry Form: https://www.shionogi.com/global/en/contact.html

🧩 Final Takeaway

GSK has successfully simplified the ownership of its key HIV business, ViiV Healthcare, by having Shionogi buy out Pfizer's stake. GSK maintains full control, gains a $250 million cash dividend, and strengthens its strategic partnership with Shionogi, all while cleaning up its balance sheet.